2023 PreprintHelp me understand this report
Supplementary Figure S2 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Abstract: <p>Consort diagram of the clinical trial.Abbreviations: OS, overall survival; PFS, progression-free survival</p>
View published versions
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
